Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BDX200
- Development stage
- Unknown
- Lead developer
- Inspirevax
- Modality
- Vaccines & Immunotherapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intranasal
01
Overview
BDX200 (also known as BDX300 or FluINsure) is an intranasal subunit influenza vaccine developed by Inspirevax (originally developed by ID Biomedical and later GSK). It consists of influenza hemagglutinin (HA) antigens complexed with a proteosome adjuvant derived from outer membrane proteins (OMPs) of Neisseria meningitidis. The HA antigen induces influenza-specific adaptive immunity, while the proteosome adjuvant stimulates innate immune signaling primarily through Toll-like receptors TLR1, TLR2, and TLR4. BDX200 has been evaluated in ten clinical trials, including challenge and field studies, demonstrating a favorable safety and efficacy profile.
- Brand names
- FluINsure
- Other names
- Nasal Influenza VaccineP-TIVProteosome Nasal Influenza VaccineProteosome-adjuvanted trivalent inactivated influenza vaccine
02
Targets
HA (Hemagglutinin)TLR1TLR2 (Toll-like Receptor 2)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on BDX200.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BDX200.